News for XTL Biopharmaceuticals Ltd. (XTLB)

News for XTL Biopharmaceuticals Ltd.
Date Headline
Oct 06, 2017 07:30 AM Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy
Oct 05, 2017 07:50 AM Earnings Review and Free Research Report: DelMar Missed Earnings Expectations
Sep 26, 2017 09:23 AM XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update
Sep 12, 2017 09:00 AM XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
Jul 11, 2017 07:00 AM Featured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update
Jun 15, 2017 09:00 AM XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update
Apr 27, 2017 09:50 AM XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors
Apr 05, 2017 09:10 AM XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome
Mar 30, 2017 08:55 AM XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update
Mar 22, 2017 09:22 AM XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors